skip to content »

diabetes-endocrinology

Houston, Texas

Anatomy instruction at Baylor College of Medicine
Medicine/Endocrinology
not shown on screen

Susan L. Samson, M.D., Ph.D.

Susan L. Samson, M.D., Ph.D.Assistant Professor of Medicine
Associate Director, Endocrine Fellowship Program

Medical Director, Pituitary Center
Baylor Clinic and St. Luke's Episcopal Hospital
Endocrinology Service - Ben Taub Hospital

www.bcm.edu/neurosurgery/pituitarycenter

One Baylor Plaza, Room R615 (MS: BCM185)
Houston, TX 77030
Email: ssamson@bcm.edu

Appointments for the Pituitary Clinic 713-798-4696
Other endocrine disorders, please call 713-798-4736 for an appointment with Baylor Endocrinology

Education

  • B.Sc. Honours: Cellular, Microbial and Molecular Biology, University of Calgary, Alberta, Canada, 1990
  • Ph.D.: Molecular Biology, University of Calgary, Alberta, Canada, 1996
  • M.D.: Queen's University, Kingston, Ontario, Canada, 2000
  • Residency: Internal Medicine, University of Calgary, Alberta, Canada, 2003
  • Fellowship: Diabetes, Endocrinology & Metabolism, Baylor College of Medicine, Houston, Texas, 2006

Certification and Designations

  • Fellowship: Diabetes, Endocrinology & Metabolism, Baylor College of Medicine, Houston, Texas, 2006
  • American Board of Internal Medicine/Internal Medicine, 2003
  • Fellow of the Royal College of Physicians of Canada/Internal Medicine, 2004
  • American Board of Internal Medicine/Endocrinology, Diabetes and Metabolism, 2005
  • Fellow of the Royal College of Physicians of Canada/Endocrinology and Metabolism, 2007
  • Fellow of the American College of Endocrinology, 2010

Laboratory Research Interests

  • Role of Wnt signaling for beta cell development and function
  • Cell and gene therapy for diabetes
  • Glucagon-like peptide receptor agonists in type 1 and type 2 diabetes models

Clinical Research Interests

  • Pituitary Adenomas
  • Acromegaly

Publications

Peer-reviewed Journals

  • Samson SL* and Bajaj M. 2013. Direct actions of GLP-1 analogues on AMP-activated Protein Kinase activity are distinct from cyclic AMP accumulation. J. Hepatol. 58: 634-5. *Corresponding author
  • Samson SL* and Bajaj M. 2013. Potential of incretin-based therapies for Non-Alcoholic Fatty Liver Disease: Beyond weight loss. J Diabetes Complications.. *Corresponding author
  • Nguyen D, Samson SL, Reddy VT, Gonzalez E, Sekhar RV. 2013. Glutathione restoration corrects impaired fatty-acid oxidation and decreases insulin resistance in old mice and elderly humans. Aging cell.
  • Samson SL and Garber A. 2013. GLP-1 agonist therapy for diabetes: potential benefits and risks. Current Opinion in Endocrinology and Diabetes 20: 87-97.
  • Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, Muthupillai R, Chan L, Bajaj M (2011) Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity & in a drandomised controlled trial. Diabetologia. Dec;54(12):3093-100. PMID: 21956711
  • Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M (2011) Effects of combined exenatide & pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring). Dec;19(12):2310-5. PMID: 21660077
  • Samson SL, Gonzalez EV, Yechoor V, Bajaj M, Oka K, Chan L (2009) Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther. Oct;17(10):1831 PMCID: PMC2582376
  • Samson SL, Kohjima M, Chan L (2009) News and commentary: A fine balance - an autoregulatory gene therapy approach to treat obesity and achieve energy homeostasis. Gene Therapy 16: 1175-7. PMID 19626055          
  • Yang Y, Chang BH, Samson SL, Li MV, Chan L (2009)The Krüppel-like zinc finger protein Glis3 directly and indirectly activates insulin gene transcription. Nucleic Acids Res 37:2529-38. PMID: 19264802
  • Freedman RJ, Samson SL, Edwards AL, Schaefer JP, Southern DA, Quan H, Ghali WA. 2007. Glycemic control and use of the insulin sliding scale in hospitalized patients with diabetes. J Healthcare Qual 29: 37-43. PMID: 17465168
  • Yechoor V, Liu V, Paul A, Burras EB, Ozer K, Samson SL, and Chan L (2009). Hepatic gene therapy with Neurogenin3 and betacellulin reverses major metabolic problems in insulin-deficient diabetic mice. Endocrinology 150: 4863-73. PMID: 19819964
  • Samson SL, Pownall HJ, Scott L, O’Brien Smith EO, Sekhar RV, Ballantyne CM, Balasubramanyam A (2006) Heart Positive: Design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy / dyslipidemia. Contemp Clin Trials 27: 518-530. PMID: 1691439
  • Samson SL, Chan L (2006). Gene therapy for diabetes: Re-inventing the islet. Trends Endo Metab 17: 92-100. PMID: 1650453410

Book Chapters

  • Shah B, and Samson SL. 2011. Hyponatremia. In, Conn’s Current Therapy 63nd edition (Rakel RF, Bope ET, eds.), WB Saunders Company,pp. 608-614.
  • Samson SL. 2011. Incretin therapies for type 2 diabetes: the liver takes a bow. Treatment Strategies: Diabetes. 3: 93-97.
  • Gonzalez EV, and Samson SL. 2010. Hypopituitarism. In, Conn’s Current Therapy 62nd edition (Rakel RF, Bope ET, eds.), WB Saunders Company, pp.664-670.
  • Samson SL, Yechoor V, Chan L. 2008. Molecular Therapy for Type 1 and Type 2 Diabetes. In, Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 3rd edition. (Templeton NS, ed). Marcel Dekkar, NY.

E-mail this page to a friend